Related Experiment Video
Updated: May 18, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Recurrence of IgG4-related disease following treatment with rituximab
Jun Murakami1, Shoko Matsui, Shin Ishizawa
1Department of Internal Medicine (3), Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan, jmura-tym@umin.ac.jp.
Abstract:
A 54-year-old woman with suspected low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type of the eyelids underwent rituximab-containing chemotherapy. She initially responded to the rituximab therapy, but later experienced two recurrences over a 3-year period. Biopsy specimens and a review of her previous histology revealed that she had had immunoglobulin G4-related disease at the initial presentation. Although IgG4-related disease seems to respond well to rituximab therapy, long-term follow up, including disease monitoring, is needed to evaluate disease remission.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Hypersensitivity Reactions: Immune-Complex Reactions
Rheumatic Heart Disease I: Introduction